News from mind medicine (mindmed) inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 26, 2021, 13:48 ET MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF, DE: MMQ) ("MindMed"), a leading psychedelic medicine biotech company, is pleased to announce...

Feb 18, 2021, 07:30 ET MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, announced that it will acquire HealthMode, a digital...

Feb 17, 2021, 07:30 ET MindMed's LSD Neutralizer Study Begins

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD...

Feb 11, 2021, 07:30 ET MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift ...

Feb 02, 2021, 07:30 ET MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company, streamlined its leadership team to further develop the...

Jan 20, 2021, 07:30 ET MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical...

Jan 14, 2021, 07:30 ET MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an...

Jan 12, 2021, 07:30 ET MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomized...

Dec 14, 2020, 07:30 ET MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND...

Nov 24, 2020, 07:30 ET MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as...

Nov 16, 2020, 07:30 ET MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its protocol...

Nov 13, 2020, 18:20 ET MindMed Announces Q3 2020 Financial Results;

MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three...

Nov 02, 2020, 07:30 ET MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab...

Oct 05, 2020, 05:00 ET MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today...

Sep 24, 2020, 07:30 ET MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading drug development company for psychedelic inspired medicines, announces that the...

Sep 23, 2020, 11:39 ET MindMed Confirms No Material Change

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the ...

Sep 21, 2020, 07:30 ET MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is...

Aug 25, 2020, 07:30 ET MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines and the...

Aug 20, 2020, 20:03 ET Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial...

Aug 13, 2020, 07:30 ET MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its presence in Europe. The leading neuro-pharmaceutical company for psychedelic...

Aug 06, 2020, 07:30 ET MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted...

Jul 28, 2020, 07:30 ET MindMed Completes Dosing 18-MC Phase 1 Study

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single...

Jun 26, 2020, 17:41 ET MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D...

Jun 24, 2020, 00:05 ET MindMed Developing IP For Personalized Psychedelic Assisted Therapies

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing...

Jun 18, 2020, 07:00 ET MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

MindMed will now pursue N,N-Dimethyltryptamine (DMT), the principally active ingredient in Ayahuasca, as part of its R&D collaboration with the...